Skip to content

Gilead files supplemental U.S. application for expanded use of Yescarta

September 4, 2020

Gilead Sciences (NASDAQ:GILD) unit Kite has filed a supplemental marketing application to the FDA seeking approval of Yescarta (axicabtagene ciloleucel) for the treatment of relapsed/refractory follicular lymphoma and marginal zone lymphoma after two or more prior lines of systemic therapy, both Breakthrough Therapy-tagged indications.

The CAR T therapy was approved in the U.S. almost three years ago for certain types of non-Hodgkin lymphoma.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: